INTRODUCTION: In this talk, Dr David Erritzoe will outline the field, from the psychological and neurobiological role of psychedelics in increasing flexibility in “stuck” brain networks to key findings from recent clinical trials. He will then examine the practical realities of implementation, exploring how healthcare systems can prepare for the emerging wave of psychedelic therapies. Using ketamine service pilots as an example, David will show how collaboration between public health systems and new treatments can provide a balanced, scalable path forward — expanding access while strengthening the evidence base within existing care structures.

AIM(S): NA

METHOD(S): NA

RESULTS: NA

CONCLUSIONS: NA

FINANCIAL SUPPORT: NA